Stockreport

Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF – 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy –– Clinically Relevant 48% hsCRP Reduction –– The Combination Therapy Was Observed to b [Read more]